MarketsandMarkets is here with a platform for pharmaceutical, biotechnology professionals and technology providers to come together at the BioGeNe 2023 Confex on the 8th - 9th February 2023 in San Diego-USA to discuss advancements and solutions to the most critical challenges in the Biomarker, Microbiome and Genome engineering areas.
Drug discovery businesses have begun to invest in cutting-edge methods for biomarker discovery because of mounting demands related to the success rates of FDA-approved biomarkers and associated diagnostic tests. Speakers are to discuss about Biomarker and Companion Diagnostics and Microbiome and Probiotics. In the past year, the genome editing sector has seen some impressive advancements in the fields of genome writing, base editing, and specific advancements in the treatments using Car-T cells and immunotherapy. Numerous small innovative businesses are present in the market because of the growing emphasis on the development of probiotics products and drugs as well as human microbiome therapies.
The two conferences which are going to be a part of BioGeNe Confex 2023 are, 8th Annual MarketsandMarkets Biomarker and Companion Diagnostics and 5th Annual MarketsandMarkets Next Gen Microbiome and Probiotics .
Director, Research Collaborations, Washington University School of Medicine
CEO, Evimero
Professor of Food Microbiology, Chair, Interdepartmental Food Science Graduate Program, Department of Food Science, Purdue Institute of Inflammation, Immunology and Infectious Disease
CEO, ProSperity Bioscience
Chief Scientific Officer, Dakota Biotech
Global Director, Biomarkers and CDx, BD Biosciences Biosciences
Director Companion Diagnostics Business Development, Qiagen
Leader – Complex Microbial Systems Group, NIST - National Institute of Standards and Technology
Director, George Washington School of Medicine & Health Sciences
Chief Executive Officer and Founder, Symbiome
CEO, Phi Therapeutics
CEO and Founder, Cybele Microbiome
CEO, Primal Health Inc.
Professor of Food Microbiology, Chair, Interdepartmental Food Science Graduate Program, Department of Food Science, Purdue Institute of Inflammation, Immunology and Infectious Disease
CEO, ProSperity Bioscience
Vice President, Head, Translational Medicine, , Syncopation Lifesciences
Associate Director, Medical & Scientific Affairs, BD Biosciences
Director, Translational Sciences, Bicycle Therapeutics
CEO, Bionavigen
Senior Director, Clinical Biomarkers, Poseida Therapeutics
Principal Scientist, Gritstone Oncology
Scientist, Sorrento Therapeutics
Partner, HGF IP Limited
Chief Scientific Officer, Proteome Sciences PLC
Director, Companion Diagnostics, Merck
CEO, Evimero
Associate Professor, Molecular Biology and Biochemistry School of Biological Sciences,, University of California Irvine
Associate Professor of Medicine, Director, UNC Microbiome Core, School of Medicine, University of North Carolina at Chapel Hill
VP of Research and Product Development, Symbiome
PhD student | Department of Chemistry and Bioscience, Aalborg University
Senior Biomarker Scientist, Owlstone Medical
CEO, BioForm Solutions
Professor emeritus of Pathology and Environmental Health Sciences and Radiation Oncology, UCLA Schools of Medicine and Public Health
Director, Research Collaborations, Washington University School of Medicine
Distinguished Research Staff Member, Oak Ridge National Laboratory
University Academic fellow (Bioinformatics lead), University of Leeds
Microbiome Scientist at Department of Pathology, Wake Forest School of Medicine, NC.
Professor, Huntsman Cancer Institute, University of Utah
President, CEO, GeneCentric Therapeutics
CEO and Founder, Thirty-Six
Co-director of the California Initiative to Advance Precision Medicine in the California Governor’s Office of Planning and Research,
Regional Medical Affairs Director, Mirati Therapeutics
CEO, Precision Antibody, A&G Pharmaceutical, Inc. | Precision Antibody
Assistant Professor, Cedars-Sinai Medical Center
Associate Director, Bristol-Myers Squibb
Double Tree by Hilton, San Diego - Mission Valley
